Novel platelet inhibitors

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 161-184

  Bennett, J S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aspirin; GPIIb IIIa antagonists; Platelet aggregation; Thienopyridines

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR; INTEGRIN; MONOCLONAL ANTIBODY; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN SYNTHASE; TICLOPIDINE;

CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ARTERIOSCLEROSIS; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; HUMANS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0035120357     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.161     Document Type: Review

References (132)

1. The hemostatic plug
2. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
3. Multiple very late antigen (VLA) heterodimers on platelets. Evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 structures
4. Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion
5. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: Additional evidence in support of GPIb as a platelet receptor for von Willebrand factor
6. Platelets have more than one binding site for von Willebrand factor
7. Structure and function of the glycoprotein Ib-IX-V complex
8. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow
9. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to Fc R and the natural killer receptors
10. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion
11. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia
12. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency
13. Structural biology of glycoprotein IIb-IIIa
14. A dual thrombin receptor system for platelet activation
15. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
16. Characterization of a functional thrombin receptor. Issues and opportunities
17. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation
18. Molecular basis for ADP-induced platelet aggregation. I. Evidence for three distinct ADP-receptors on human platelets
19. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets
20. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation
21. Glycoprotein VI is a major collagen receptor for platelet activation: It recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not
22. Primary haemostasis: Sticky fingers cement the relationship
23. 2a receptors
24. 2A-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels
25. Molecular basis for platelet activation
26. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
27. Cloning and expression of cDNA for a human thromboxane A2 receptor
28. Pharmacological receptors on blood platelets
29. Activation of V1-receptors by vasopressin stimulates inositol phospholipid hydrolysis and arachidonate metabolism in human platelets
30. Platelet-activating factor: Receptors and signal transduction
31. Receptors linked to inhibition of adenylate cyclase: Additional signaling mechanisms
32. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity
33. Interaction of nitric oxide and cGMP with signal transduction in activated platelets
34. Role of intracellular signaling events in ADP-induced platelet aggregation
35. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationships of peptides corresponding to the carboxy-terminal segment of the γ chain
36. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets
37. Interaction of fibrinogen with its platelet receptor. Differential effects of α and γ chain fibrinogen peptides on the glycoprotein IIb-IIIa complex
38. Interrelations of platelet aggregation and secretion
39. Reconstitution of ATP-dependent aminophospholipid translocation in proteoliposomes
40. A subfamily of P-type ATPases with aminophospholipid transporting activity
41. 2+-dependent transbilayer migration of membrane phospholipids
42. Aspirin as an antiplatelet drug
43. The bleeding time response to aspirin
44. 2 but not systemic prostacyclin by controlled-release aspirin
45. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
46. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction: ISIS-2
47. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, stroke by prolonged antiplatelet therapy in various categories of patients
48. Randomized trial of prophylactic daily aspirin in British male doctors
49. Final report on the aspirin component of the ongoing physicians' health study
50. 114. Low dose aspirin therapy for chronic stable angina
51. 2-receptor blockade
52. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction: The ridogrel versus aspirin patency trial (RAPT)
53. ADP receptors and clinical bleeding disorders
54. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors
55. ac ADP receptor-mediated signaling by the antiplatelet drug clopidogrel
56. Antiplatelet drugs. A comparative review
57. Ticlopidine and clopidogrel
58. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial
59. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
60. The STIMS trial: The ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study
61. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
62. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs
63. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
64. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators
65. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy
66. Ticlopidine-associated aplastic anemia. A case report and review of literature
67. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention
68. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
69. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases
70. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement
71. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
72. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting
73. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
74. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
75. Clopidogrel versus ticlopidine after intracoronary stent placement
76. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
77. Thrombotic thrombocytopenic purpura associated with clopidogrel
78. Dipyridamole
79. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
80. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor
81. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
82. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
83. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
84. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators
85. Usefulness of cilostazol versus ticlopidine in coronary artery stenting
86. Comparison of cilostazol versus ticlopidine therapy after stent implantation
87. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39
88. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation
89. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39
90. Blockade and reversal of human platelet reactivity by CD39/ectoADPase. Potential for antithrombotic therapeusis
91. Development of potent thrombin receptor antagonist peptides
92. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor
93. Design and synthesis of parafluorophenylalanine amide derivatives as thrombin receptor antagonists
94. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb-IIIa complex
95. Binding of abciximab to αVβ3 and activated αMβ2 receptors: With a review of platelet-leukocyte interactions
96. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
97. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
98. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment
99. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
100. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
101. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
102. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels, c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators
103. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators
104. Randomised placebo-controlled and balloonangioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting
105. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of platelet IIb/IIIa inhibition in Stenting Investigators
106. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting
107. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy
108. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: Results of the EPISTENT trial
109. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins
110. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction
111. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors
112. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy
113. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa
114. Readministration of abciximab: Interim report of the ReoPro readministration registry
115. Clinical pharmacology of eptifibatide
116. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
117. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
118. Design and methodology of the PURSUIT trial: Evaluating eptifibatide for acute ischemic coronary syndromes. Platelet glycoprotein IIb-IIIa in unstable angina: Receptor suppression using integrilin therapy
119. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II
120. Tirofiban (Aggrastat®)
121. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp
122. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis
123. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis
124. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
125. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet receptor inhibition in ischemic syndrome management
126. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
127. Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: Issues and opportunities
128. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: Fact or fancy?
129. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial
130. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
131. Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology